Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year. Marstacimab will be ...

He is cautioning investors against consumer staples and utilities. At the same time, Eric Teal, chief investment officer for Comerica (NYSE:CMA) Wealth Management, expects the Dow to end the year ...

Story May 1 - Arvinas: After Arvinas announced during its Q1 results presentation that the biotech and partner Pfizer are dropping two phase 3 trials from their estrogen receptor degrader R&D plan ...